Study design
PsA, tumor necrosis
TUMOR NECROSIS
This post hoc analysis included pooled data from two phase 3 studies of tofacitinib for the treatment of active PsA: OPAL Broaden (NCT01877668) [OPAL Broaden was a 12-month study of tofacitinib in tumor necrosis factor inhibitor (TNFi)-naïve patients with an inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD). Patients received tofacitinib 5 or 10 mg BID, adalimumab 40 mg subcutaneous injection once every 2 weeks, or placebo (advancing to tofacitinib 5 or 10 mg BID at month 3) [This post hoc analysis included patients receiving tofacitinib 5 or 10 mg BID to month 6, or placebo to month 3.Both studies were conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. The study protocols were reviewed and approved by the Institutional Review Boards and/or an Independent Ethics Committee at each study center, and all patients provided written, informed consent.